MEDSTONE STS-TC/U LITHOTRIPTER

FDA Premarket Approval P970042 S003

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the sts-tc/u lithotripter (transportable version of the sts lithotripter with ultrasound). The device, as modified, will be marketed under the trade name medstone sts-tc/u lithotripter and is indicated for 1) the fragmentation of symptomatic upper urinary tract stones, i. E. , renal calyceal stones, renal pelvic stones, and upper ureteral stones, and 2) when used in conjunction with certain ursodiols, is indicated for the treatment of symptomatic, solitary, radiolucent, non-calcified gallstones (between 4 and 20 mm in maximum diameter) in adult patients for whom surgical removal of the gallbladder is medically contraindicated and in symptomatic high-risk patients who have actively refused surgery. Combination therapy consists of 1) administration of novartis pharmaceutical actigall. , or amide pharmaceutical ursodiol, or teva pharmaceutical ursodiol (8-10 mg/kg/day) for at least two weeks pre-lithotripsy, 2) lithotripsy treatments of up to 2000 24 kv shocks, and 3) continued administration of ursodiol until a stone-free state is achieved.

DeviceMEDSTONE STS-TC/U LITHOTRIPTER
Generic NameLithotripter, Shockwave (for Treating Gallbladder Stones)
ApplicantMEDSTONE INTL., INC.
Date Received2002-07-03
Decision Date2003-02-14
PMAP970042
SupplementS003
Advisory CommitteeGastroenterology/Urology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product Yes
Applicant Address MEDSTONE INTL., INC. 100 Columbia, Suite 100 aliso Viejo, CA 92656-4114

Supplemental Filings

Supplement NumberDateSupplement Type
P970042Original Filing
S004 2002-08-02 Normal 180 Day Track
S003 2002-07-03 Normal 180 Day Track
S002 2002-02-21 Normal 180 Day Track
S001 2000-12-18 Normal 180 Day Track

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.